Table 4.
Breast Cancer.
| Reference | Type of study | Site | n | Treatment | Tumor response | Survival | HT-associated adverse events |
|---|---|---|---|---|---|---|---|
| De-Colle et al42 | Prospective observational study | Recurrent breast cancer | 20 | RT + HT | Clinical benefit = 90% | 2 years: OS = 90% and DFS = 90% 5 years: OS = 50% |
>G3 toxicity in 15% |
| Klimanov et al37 | Metastatic breast cancer | 103 | 53 CHT + HT 50 CHT |
Clinical benefit = 76% (CHT + HT) vs 42% (CHT), P < .05 | |||
| Linthorst et al39 | Recurrent breast cancer | 248 | RT + HT | CR rate 70% 1-, 3-, and 5-year LC was 53%, 40%, and 39%, respectively |
SR at 1, 3, and 5 years = 66%, 32%, and 18%, respectively | ||
| Oldenborg et al40 | Recurrent breast cancer | 404 | RT + HT | CR = 86% ORR was 86%. 3-year LC rate was 25% |
Median = 17 months and SR at 3 year = 37% | >G3 toxicity in 24% | |
| Refaat et al43 | Recurrent or advanced breast cancer | 127 | RT + HT | CR =52.7% LC = 55.1% |
SR at 1, 3, and 5 years = 58.3%, 29.5%, and 22.5%, respectively | ||
| Linthorst et al41 | Recurrent breast cancer | 198 | RT + HT | Median = 82 months SR at 3, 5, and 10 years = 75%, 60%, and 36%, respectively |
G3-G4 toxicity in 10% | ||
| Takeda et al36 | Recurrent or advanced breast cancer | 172 | Immunotherapy + HT | Clinical benefit = 17.6% effective rate of immunotherapy increased from 7.7% to 26.0% using HT | |||
| Varma et al44 | Advanced breast carcinoma | 59 | RT + HT | LC = 70% | >G3 toxicity in 14% | ||
| Oldenborg et al38 | Recurrent breast cancer | 78 | RT + HT | 3- and 5-year LC rates were 78% and 65% | 3-year survival 66% | G3 toxicity in 32% |
Abbreviations: HT, hyperthermia; RT, radiotherapy; clinical benefit, complete response + partial response + stable disease; OS, overall survival; DFS, disease-free survival; G, grade; CHT, chemotherapy; CR, complete response; SR, survival rate; ORR, overall response rate; LC, local control.